YM060
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diarrhea-predominant Irritable Bowel Syndrome
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Trial Timeline
Sep 1, 2012 → May 1, 2014
NCT ID
NCT01736423About YM060
YM060 is a phase 3 stage product being developed by Astellas Pharma for Diarrhea-predominant Irritable Bowel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT01736423. Target conditions include Diarrhea-predominant Irritable Bowel Syndrome.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00189696 | Phase 3 | Completed |
| NCT01736423 | Phase 3 | Completed |
| NCT01394653 | Phase 1 | Completed |
| NCT01392794 | Phase 1 | Completed |
| NCT00189813 | Phase 2 | Completed |
Competing Products
3 competing products in Diarrhea-predominant Irritable Bowel Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YM060 + Placebo | Astellas Pharma | Phase 3 | 77 |
| Ramosetron | Astellas Pharma | Pre-clinical | 23 |
| Rifamycin SV 600mg t.i.d. + Rifamycin SV b.i.d. + Placebo + Placebo t.i.d. | Cosmo Pharmaceuticals | Phase 2 | 47 |